S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:SELB

Selecta Biosciences (SELB) Stock Forecast, Price & News

$1.37
+0.01 (+0.74%)
(As of 06/8/2023 ET)
Compare
Today's Range
$1.33
$1.41
50-Day Range
$1.04
$1.40
52-Week Range
$0.90
$2.73
Volume
925,338 shs
Average Volume
1.18 million shs
Market Capitalization
$210.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Selecta Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
319.7% Upside
$5.75 Price Target
Short Interest
Bearish
6.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.71mentions of Selecta Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.39) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

161st out of 981 stocks

Pharmaceutical Preparations Industry

69th out of 478 stocks


SELB stock logo

About Selecta Biosciences (NASDAQ:SELB) Stock

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
What 6 Analyst Ratings Have To Say About Selecta Biosciences
See More Headlines

SELB Price History

SELB Company Calendar

Last Earnings
5/04/2023
Today
6/08/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SELB
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.75
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+331.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$35.38 million
Pretax Margin
-18.95%

Debt

Sales & Book Value

Annual Sales
$110.78 million
Cash Flow
$0.09 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
105,558,000
Market Cap
$213.27 million
Optionable
Optionable
Beta
1.17

Key Executives

  • Carsten BrunnCarsten Brunn
    President, Chief Executive Officer & Director
  • Lloyd Johnston
    COO, Senior Vice President-Research & Development
  • Blaine T. Davis
    Chief Financial Officer
  • Takashi Kei Kishimoto
    Chief Scientific Officer
  • Peter G. TraberPeter G. Traber
    Chief Medical Officer













SELB Stock - Frequently Asked Questions

Should I buy or sell Selecta Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SELB shares.
View SELB analyst ratings
or view top-rated stocks.

What is Selecta Biosciences' stock price forecast for 2023?

4 brokerages have issued 1 year price objectives for Selecta Biosciences' shares. Their SELB share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's stock price to reach $5.75 in the next year. This suggests a possible upside of 313.7% from the stock's current price.
View analysts price targets for SELB
or view top-rated stocks among Wall Street analysts.

How have SELB shares performed in 2023?

Selecta Biosciences' stock was trading at $1.13 at the beginning of 2023. Since then, SELB stock has increased by 23.0% and is now trading at $1.39.
View the best growth stocks for 2023 here
.

When is Selecta Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SELB earnings forecast
.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03. The company had revenue of $5.94 million for the quarter, compared to analyst estimates of $14.60 million. Selecta Biosciences had a negative net margin of 18.21% and a negative trailing twelve-month return on equity of 17.67%.

What ETFs hold Selecta Biosciences' stock?

ETFs with the largest weight of Selecta Biosciences (NASDAQ:SELB) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).First Trust Dow Jones Select Microcap Index Fund (FDM).

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.57%), Sphera Funds Management LTD. (1.52%), JPMorgan Chase & Co. (1.30%), Acadian Asset Management LLC (0.98%), Geode Capital Management LLC (0.79%) and Renaissance Technologies LLC (0.70%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends
.

How do I buy shares of Selecta Biosciences?

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $1.39.

How much money does Selecta Biosciences make?

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $213.27 million and generates $110.78 million in revenue each year. The company earns $35.38 million in net income (profit) each year or ($0.09) on an earnings per share basis.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.

This page (NASDAQ:SELB) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -